← Product Code [JDI](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JDI) · K123501 # OSS MODULAR STEMS, OSS DIAPHYSEAL SEGMENTS (K123501) _Biomet, Inc. · JDI · Feb 27, 2013 · Orthopedic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JDI/K123501 ## Device Facts - **Applicant:** Biomet, Inc. - **Product Code:** [JDI](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JDI.md) - **Decision Date:** Feb 27, 2013 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 888.3350 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Intended Use The Orthopedic Salvage System components are intended for cemented use only unless used in a proximal femoral replacement application. Biomet's Segmental Femoral Replacement components are intended for use in total knee, total hip, or total femoral replacement procedures. Specific indications are: 1. Painful and disabled joint resulting from avascular necrosis, osteoarthritis, rheumatoid arthritis, or traumatic arthritis. 2. Correction of varus, valgus or post-traumatic deformity. 3. Correction or revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement. 4. Ligament deficiencies. 5. Tumor resections. 6. Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques. 7. Revision of previously failed total joint arthroplasty. 8. Trauma. These devices are to be used with bone cement unless a proximal femur is indicated for use (USA). When components of the Orthopedic Salvage System are used with Biomet's Compress Segmental Femoral Replacement System, they are intended for uncemented application and indicated for: 1. Correction or revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement. 2. Tumor resections. 3. Revision of previously failed total joint arthroplasty. 4. Trauma. ## Device Story Orthopedic Salvage System (OSS) is a modular component set for complex revision surgeries and limb salvage. Components replace portions of or total femur, knee, and proximal tibia. Modification involves transitioning male tapers from machined to roller-hardened and machined surfaces. Used in clinical settings by orthopedic surgeons. Device provides structural replacement for diseased or damaged bone/joint tissue; improves patient mobility and function. Bench testing confirms roller-hardened tapers exhibit superior or equivalent fatigue strength and pull-off resistance compared to predicate. ## Clinical Evidence No clinical data. Substantial equivalence demonstrated via non-clinical bench testing, including cantilever fatigue, compressive fatigue, and static axial separation testing. ## Technological Characteristics Modular orthopedic prosthesis components. Modification: roller-hardened and machined male tapers. Materials: metal/polymer. Energy source: N/A (mechanical). Connectivity: N/A. Sterilization: Not specified. ## Regulatory Identification A hip joint metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and an acetabular resurfacing component made of ultra-high molecular weight polyethylene and is limited to those prostheses intended for use with bone cement (§ 888.3027). ## Predicate Devices - Oncology Salvage System (Biomet) ([K002757](/device/K002757.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logo for BIOMET MANUFACTURING CORP. The word "BIOMET" is in a stylized font with a thick outline. Below the logo, the words "MANUFACTURING CORP." are printed in a simple, sans-serif font. The text is black and the background is white. K12350 (pg 1/3) # FEB 2 7 2013 #### 510(k) Summary Preparation Date: 23 October, 2012 Applicant/Sponsor: Biomet Manufacturing Corp. 56 East Bell Drive Warsaw, IN 46582 FDA Registration #: 1825034 Contact Person: Gary Baker Sr. Regulatory Specialist 56 East Bell Drive Warsaw, IN 46582 574-267-6639 Ext. 1568 574-371-1027 gary.baker@biomet.com Proprietary Name: · Orthopedic Salvage System (OSS) Constrained knee Common Name: Classification Code(s)/Name(s): JDI, KRO 888.3350 (JDI) - Hip joint metal/polymer semi-constrained cemented prosthesis. 888.3510 (KRO) - Knee joint femorotibial metal/polymer constrained cemented prosthesis # Legally Marketed Devices To Which Substantial Equivalence Is Claimed: K002757 - Oncology Salvage System (Biomet) ### Device Description: The Orthopedic Salvage System is a system of modular components that are intended to be used for difficult revision surgeries or limb salvage procedures. The components can replace any portion of, or the total femur and/or the knee and proximal tibia. # Intended Use: The Orthopedic Salvage System components are intended for cemented use only unless used in a proximal femoral replacement application. Mailing Address: P.O. Box 587 Warsaw, IN 46581-0587 Toll Free: 800.348.9500 Office: 574.267.6639 Main Fax: 574.267.8137 www.biomet.com {1}------------------------------------------------ # Indications For Use: Biomet's Segmental Femoral Replacement components are intended for use in total knee, total hip, or total femoral replacement procedures. Specific indications are: - 1. Painful and disabled joint resulting from avascular necrosis, osteoarthritis, rheumatoid arthritis, or traumatic arthritis. - 2. Correction of varus, valgus or post-traumatic deformity. - 3. Correction or revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement. - 4. Ligament deficiencies. - 5. Tumor resections. - 6. Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques. * - 7. Revision of previously failed total joint arthroplasty. - 8. Trauma. These devices are to be used with bone cement unless a proximal femur is indicated for use (USA). *Not applicable to Regenerex Ultra Porous Construct titanium knee augment usage (not licensed in Canada), or any other knee component. When components of the Orthopedic Salvage System are used with Biomet's Compress Segmental Femoral Replacement System, they are intended for uncemented application and indicated for: - 1. Correction or revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement. - 2. Tumor resections. - 3. Revision of previously failed total joint arthroplasty. - 4. Trauma. # Summarv of Technologies: The modifications proposed within this submission include expanding the product line and modifying the male tapers from a machined taper to a roller hardened and machined taper. # Non-Clinical Testing: Cantilever Fatigue testing was conducted to evaluate the taper cantilever fatigue strength and compare the results with the cantilever fatigue strength of the predicate tapers. Results determined that the roller hardened tapers were stronger in cantilever fatigue than the predicate tapers. The acceptance criteria were met. Compressive Fatigue testing was conducted to evaluate the taper compressive fatigue strength and compare the results with the compressive fatigue strength of the predicate tapers. Results determined that the compressive fatigue strength of the roller hardened tapers was equivalent to or greater than the compressive fatigue strength of the predicate tapers. The acceptance criteria were met. {2}------------------------------------------------ K123501 (pg 3/3) Static Axial Separation testing was conducted to evaluate the pull-off strength of the taper junction and compare the results with the pull-off strength of the taper junction of the predicate tapers. Results determined that the pull-off strength of the roller hardened tapers was equivalent to or greater than the pull-off strength of the predicate tapers. The acceptance criteria were met. # Clinical Testing: Clinical testing was not required to demonstrate substantial equivalence of the design modifications proposed to the cleared predicate devices. All trademarks are property of Biomet, Inc. {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" arranged in a circular fashion around the symbol. The text is in all caps and is in a sans-serif font. The logo is black and white. #### Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 February 27, 2013 Biomet Manufacturing Corp. % Mr. Gary Baker Senior Regulatory Specialist 56 East Bell Drive Warsaw, Indiana 46582 Re: K123501 Trade/Device Name: Orthopedic Salvage System Regulation Number: 21 CFR 888.3350 Regulation Name: Hip joint metal/polymer semi-constrained cemented prosthesis Regulatory Class: Class II Product Code: JDI, KRO Dated: January 11, 2013 Received: January 28, 2013 Dear Mr. Baker: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set {4}------------------------------------------------ # Page 2 - Mr. Gary Baker forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely yours, ErinI.D.Keith Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ #### Indications for Use 510(k) Number (if known): _______K123501 Device Name: Orthopedic Salvage System #### Indications for Use: Biomet's Segmental Femoral Replacement components are intended for use in total knee, total hip, or total femoral replacement procedures. Specific indications are: - 1. Painful and disabled joint resulting from avascular necrosis, osteoarthritis, rheumatoid arthritis, or traumatic arthritis. - 2. Correction of varus, valgus or post-traumatic deformity. - 3. Correction or revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement. - 4. Ligament deficiencies. - 5. Tumor resections. - 6. Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femirr with head involvement, unmanageable by other techniques. * - 7. Revision of previously failed total joint arthroplasty. - 8. Trauma. These devices are to be used with bone cement unless a proximal femur is indicated for use (USA). *Not applicable to Regenerex Ultra Porous Construct titanium knee augment usage (not licensed in Canada), or any other knee component. When components of the Orthopedie Salvage System are used with Biomet's Compress Segmental Femoral Replacement System, there intended for uncemented application and indicated for: 1. Correction or revision of unsucessful osteotomy, arthrodesis, or previous joint replacement. - 2. Tumor resections. - 3. Revision of previously fuiled total joint arthroplasty. - 4. Traumu Prescription Use _ YES __ AND/OR Over-The-Counter Use NO NO ____(Part (21 CFR 807 Subpart C) 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Elizabethi i Mrank -S Division of Orthopedic Devices 10 Page 1 of 1 --- **Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JDI/K123501](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JDI/K123501) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com